Loading...
•
Mar 31, 2024
Cencora Q2 2024 Earnings Report
Cencora reported a revenue increase of 7.8% year-over-year, with GAAP diluted EPS at $2.09 and adjusted diluted EPS at $3.80.
Key Takeaways
Cencora reported a strong second quarter with revenue increasing by 7.8% year-over-year to $68.4 billion. GAAP diluted EPS was $2.09, while adjusted diluted EPS increased by 8.6% to $3.80. The company raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.30 to $13.50.
Revenue increased by 7.8% year-over-year to $68.4 billion.
GAAP diluted EPS was $2.09, compared to $2.13 in the prior year.
Adjusted diluted EPS increased by 8.6% to $3.80, from $3.50 in the prior year.
Adjusted diluted EPS guidance raised to $13.30 to $13.50 for fiscal year 2024.
Cencora
Cencora
Cencora Revenue by Segment
Cencora Revenue by Geographic Location
Revenue by Segment
U.S. Healthcare Revenue
CapyFin.comIntl. Healthcare Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Cencora updated its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year and a higher effective tax rate and expected share count.
Positive Outlook
- Adjusted diluted earnings per share to be in the range of $13.30 to $13.50.
- International Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent.
- Adjusted consolidated operating income growth to be in the range of 9 to 11 percent.
- U.S. Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent.
- Weighted average diluted shares outstanding are expected to be approximately 201 to 202 million.
Challenges Ahead
- The Company does not expect exclusive COVID-19 therapy contributions for the balance of fiscal 2024
- Adjusted effective tax rate to be approximately 21 percent.
Revenue & Expenses
Visualization of income flow from segment revenue to net income